Includes a $747.4 million benefit for deferred income taxes for the nine months ended June 30, 2018, primarily as a result of applying a lower U.S. federal income tax rate to the Company's net deferred tax liabilities as of December 31, 2017 in connection with tax reform. Purchases of common stock in the nine months ended June 30, 2019 includes $24.0 million of September 2018 purchases that cash settled in October 2018 and excludes $0.1 million of June 2019 purchases that cash settled in July 2019. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $0.63 …
VALLEY FORGE, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE:ABC) today reported that in its fiscal year 2019 fourth quarter ended September 30, 2019, revenue increased 5.4 percent to $45.6 billion. You can sign up for additional alert options at any time.At AmerisourceBergen Corporation, we promise to treat your data with respect and will not share your information with any third party. If you experience any issues with this process, please contact us for further assistance. The Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable significance of which cannot be determined, is not available and cannot be reasonably estimated. To supplement the financial measures prepared in accordance with U.S. generally accepted accounting principles (GAAP), the Company uses the non-GAAP financial measures described below. No access code is required. Includes a $142.7 million gain from antitrust litigation settlements, a $79.7 million LIFO credit, $41.9 million of PharMEDium remediation costs, and a $22.0 million reversal of a prior period assessment relating to the New York Opioid Stewardship Act in the nine months ended June 30, 2019. AmerisourceBergen Corporation provides pharmaceutical services. Therefore, the Company believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and facilitates additional analysis by, investors. Note: For more information related to non-GAAP financial measures, refer to the section titled "Supplemental Information Regarding Non-GAAP Financial Measures" of this release. Pharmaceutical Distribution Services revenue was

To access the telephone replay from within the U.S., dial (800) 475-6701.

Note: For more information related to non-GAAP financial measures, refer to the section titled "Supplemental Information Regarding Non-GAAP Financial Measures" of this release. Includes a $13.7 million gain on the sale of an equity investment in the nine months ended June 30, 2019. All values USD millions. Net cash (used in) provided by financing activities You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. These statements are not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated. Aug. 1, 2019- AmerisourceBergen Corporation (NYSE:ABC) today reported that in its fiscal year 2019 third quarter ended June 30, 2019 , revenue increased 4.9 percent to $45.2 billion . “We are extremely pleased with the continued overall strong performance by both the Pharmaceutical Distribution Services and Adjusted diluted EPS, which … Includes a LIFO credit of $16.1 million for the nine months ended June 30, 2018. AmerisourceBergen revenue was $179.59 b in FY, 2019 which is a 6.9% year over year increase from the previous period. Includes a $35.6 million gain from antitrust litigation settlements, a $16.1 million LIFO credit, and $12.0 million of PharMEDium remediation costs in the three months ended June 30, 2018. Includes a $35.9 million gain from antitrust litigation settlements, $34.5 million of PharMEDium remediation costs, and a $16.1 million LIFO credit in the nine months ended June 30, 2018. AmerisourceBergen annual revenue for 2019 was $179.589B, a 6.94% increase from 2018. The Company also provides pharmacy services to certain specialty drug patients.
Please refer to the Supplemental Information Regarding Non-GAAP Financial Measures following the tables for additional information. Replays of the call will be made available via telephone and webcast. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income. The non-GAAP financial measures should be viewed in addition to, and not in lieu of, financial measures calculated in accordance with GAAP. Smith, which was completed on January 2, 2018. We have included the following non-GAAP earnings-related financial measures in this release:


Blackrock Uk Equity Index Fund, Portal Of Loughborough University, Nj Devils Home Schedule, Nebraska Alumni Shirt, Ark Mods S+, Christopher Daniel Gibson, Gtfo R2b2 Walkthrough, Musée Fin‑de‑Siècle Museum, Idol Bts Release Date, Occupy Movement Hong Kong, Seguros Inbursa Teléfono, Tales From The Loop Tv Show, David C Driskell Artwork, Executive Protection Movie, Yaya Meaning In Text, Is Food From Ukraine Safe, Dollar Bill Values Serial Number, Loughborough University Ma Education, Are Split Ends Bad, Csl Plasma Login, Bird In Hand Dem, In Dino Dil Mera Singer, Pandora Boxx All Stars 1, Short Poem About Lightning, Aadmi 1968 Full Movie Online, Another Way To Say Native Speaker, Stephanie Bachelor Season 13 Instagram, Strong Thunderstorm Meaning, Lg Oled Gx Review, Raqib Name Meaning, Most Liked Mlb Team, Coldzera Net Worth, Goxlr Software Without Goxlr, Anthony Mcgill Masterclass, Pavitra Rishta Actress Name, Herbert Von Karajan Cause Of Death, Shostakovich Symphony No 10 Movement 2, Barry Melrose Twitter, Chiru Chiru Chinukai Song Meaning In English, Golu Real Life,